四川精神卫生
四川精神衛生
사천정신위생
SICHUAN MENTAL HEALTH
2014年
6期
522-524
,共3页
氨磺必利%度洛西汀%躯体症状%抑郁症
氨磺必利%度洛西汀%軀體癥狀%抑鬱癥
안광필리%도락서정%구체증상%억욱증
Amisulpride%Duloxetine%Somatic Symptoms%Depression
目的：探讨氨磺必利合并度洛西汀对以躯体症状为主的抑郁症的疗效及安全性。方法采用随机开放对照研究，将符合《国际疾病分类（第10版）》（ICD-10）抑郁症伴躯体症状诊断标准的60例患者按随机数字表法分为氨磺必利合并度洛西汀治疗组（研究组）和单纯度洛西汀治疗组（对照组）各30例，均治疗8周。在治疗前和治疗后2、4、6、8周末采用汉密顿抑郁量表17项版（HRSD-17）、症状自评量表（SCL-90）躯体化因子、副反应量表（ TESS）进行疗效及副作用测评。结果治疗后两组HRSD-17评分和SCL-90躯体化因子分值较治疗前差异有统计学意义（ P﹤0.01）。在治疗后第2周末起，两组HRSD-17评分和SCL-90因子分值同期比较差异有统计学意义（ P﹤0.05或0.01），两组不良反应症状均较轻，患者均能耐受，未做特殊处理。结论氨磺必利合并度洛西汀对躯体症状为主的抑郁症的疗效和安全性可能优于单一使用度洛西汀治疗。
目的：探討氨磺必利閤併度洛西汀對以軀體癥狀為主的抑鬱癥的療效及安全性。方法採用隨機開放對照研究，將符閤《國際疾病分類（第10版）》（ICD-10）抑鬱癥伴軀體癥狀診斷標準的60例患者按隨機數字錶法分為氨磺必利閤併度洛西汀治療組（研究組）和單純度洛西汀治療組（對照組）各30例，均治療8週。在治療前和治療後2、4、6、8週末採用漢密頓抑鬱量錶17項版（HRSD-17）、癥狀自評量錶（SCL-90）軀體化因子、副反應量錶（ TESS）進行療效及副作用測評。結果治療後兩組HRSD-17評分和SCL-90軀體化因子分值較治療前差異有統計學意義（ P﹤0.01）。在治療後第2週末起，兩組HRSD-17評分和SCL-90因子分值同期比較差異有統計學意義（ P﹤0.05或0.01），兩組不良反應癥狀均較輕，患者均能耐受，未做特殊處理。結論氨磺必利閤併度洛西汀對軀體癥狀為主的抑鬱癥的療效和安全性可能優于單一使用度洛西汀治療。
목적：탐토안광필리합병도락서정대이구체증상위주적억욱증적료효급안전성。방법채용수궤개방대조연구，장부합《국제질병분류（제10판）》（ICD-10）억욱증반구체증상진단표준적60례환자안수궤수자표법분위안광필리합병도락서정치료조（연구조）화단순도락서정치료조（대조조）각30례，균치료8주。재치료전화치료후2、4、6、8주말채용한밀돈억욱량표17항판（HRSD-17）、증상자평량표（SCL-90）구체화인자、부반응량표（ TESS）진행료효급부작용측평。결과치료후량조HRSD-17평분화SCL-90구체화인자분치교치료전차이유통계학의의（ P﹤0.01）。재치료후제2주말기，량조HRSD-17평분화SCL-90인자분치동기비교차이유통계학의의（ P﹤0.05혹0.01），량조불량반응증상균교경，환자균능내수，미주특수처리。결론안광필리합병도락서정대구체증상위주적억욱증적료효화안전성가능우우단일사용도락서정치료。
Objective To explore the efficacy and side effects of amisulpride combined with duloxetine in the treatment of de-pression with major somatic complains. Methods 60 depression with major somatic complains patients were randomly assigned into study group(30 cases)treated with amisulpride combined duloxetine and control group(30 cases)treated with only duloxetine. The efficacy was measured with the Hamilton Rating Scale for Depression-17 item(HRSD-17)and the somatization item of SCL-90, and side effects were evaluated with Treatment Emergent Symptom Scale( TESS)at baseline and at the end of the 2th ,4th ,6th ,8th week of the treatment. Results The reduction rates of HRSD-17 and somatization factor score of SCL-90 in study group were significantly higher than those in control group after treatment(P﹤0. 01). In the 2th,4th,6th,8th weekend of the treatment,the scores of HRSD-17 and somatization factor score of SCL-90 in study group were significantly lower than those in control group(P﹤0. 05 or 0. 01). There was no significant difference in score of TESS between the tow groups,and the side effects in two groups was not serious. Con-clusion Amisulpride combined with duloxetine in the treatment of depression with major somatic complains is effective and safety.
